FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09 juil. 2024 16h53 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
09 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10 mars 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
04 mars 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
29 févr. 2024 17h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Pricing of $150 Million Public Offering
28 févr. 2024 23h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.
Arcutis Announces Proposed Public Offering
28 févr. 2024 16h10 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 févr. 2024 05h50 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
15 déc. 2023 17h11 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...